Femasys

Femasys Enterprise Value

The Enterprise Value (EV) of Femasys (FEMY) as of Oct 22, 2026 is 25.67 M USD. In the previous year, Enterprise Value (EV) was 34.23 M USD — a change of -25.01% (lower).

Enterprise Value

25.67 MUSD

YoY

-25.01%

Last updated:

Enterprise Value (EV) of Femasys is 2025 25.67 M USD. Enterprise Value (EV) of Femasys was 2024 34.23 M USD. It decreases by -25.01% lower compared to the previous year.

The Femasys Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
24.54 M USD
Jan 1, 2020
28.97 M USD
Jan 1, 2021
6.45 M USD
Jan 1, 2022
17.82 M USD
Jan 1, 2023
15.22 M USD
Jan 1, 2024
34.23 M USD
Jan 1, 2025
25.67 M USD
The Femasys Enterprise Value history
YEAREnterprise ValueYoY
25.67 MUSD-25.01%
34.23 MUSD+124.84%
15.22 MUSD-14.57%
17.82 MUSD+176.46%
6.45 MUSD-77.75%
28.97 MUSD+18.08%
24.54 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Femasys Stock analysis

What does Femasys do? Femasys, Inc. generates revenue through the development and commercialization of its two lead product candidates, FemBloc and FemaSeed, alongside its FemEMB technology platform. FemBloc, a permanent birth control solution featuring dual intrauterine directional delivery with a degradable biopolymer, targets women seeking non-surgical contraceptive options. FemaSeed, an artificial insemination infertility treatment with single intrauterine directional delivery, addresses fertility challenges for patients. The FemEMB platform, designed for tissue sampling in physician offices, complements these products by enhancing diagnostic capabilities for women's health. These solutions are marketed to healthcare providers and clinics globally, focusing on improving patient care and health economics through office-based, non-surgical interventions. The company's revenue streams are derived from the sale of FemBloc, FemaSeed, and FemEMB to medical institutions and healthcare professionals. FemBloc targets women requiring permanent contraception, while FemaSeed serves patients with infertility issues. FemEMB supports physicians in conducting tissue sampling during routine office visits. The firm’s focus on non-surgical, office-based solutions positions it to serve a growing segment of women seeking accessible reproductive healthcare without invasive procedures. This approach aligns with the company’s mission to improve health economics by reducing the need for hospital-based interventions. Femasys, Inc. leverages its product portfolio to address key reproductive health needs through innovative, non-surgical technologies. FemBloc and FemaSeed are positioned as advanced alternatives to traditional methods, offering targeted delivery systems for contraception and fertility treatment. The FemEMB platform further enhances the company’s offerings by integrating diagnostic tools into standard office care. These products are sold to healthcare providers who serve women worldwide, emphasizing accessibility and improved patient outcomes. The company’s strategy centers on delivering solutions that meet the evolving demands of women’s healthcare in a cost-effective manner. Femasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Femasys stock

Enterprise Value (EV) of Femasys is 25.67 M USD in 2025.

Enterprise Value (EV) of Femasys changed from 34.23 M USD to 25.67 M USD, representing a -25.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Femasys since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Femasys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Femasys

All Key Metrics — Femasys